Lu Liu

Also affiliated with Soochow University, Simcere Pharmaceutical (China), Shanghai Tenth People's Hospital, Marine Biomedical Research Institute of Qingdao, Union Hospital, First Affiliated Hospital of Soochow University, Huazhong University of Science and Technology Hospital, Union Hospital, Huazhong University of Science and Technology

Biochemistry, Genetics and Molecular BiologyPhysics and AstronomyMedicineEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.4Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

End-stage renal disease is different from chronic kidney disease in upregulating ROS-modulated proinflammatory secretome in PBMCs - A novel multiple-hit model for disease progression

Redox Biology(2020)10.1016/j.redox.2020.101460

Top 16%

1.3DataRank

Top 16%56 citations

Jason Saredy, Ying Shao, Yao Tian, Lu Liu, Fatma Saaoud +19 more

Papers

Driven by 5 papers — median percentile 53. Top paper: “End-stage renal disease is different from chronic kidney disease in upregulating ROS-modulated proinflammatory secretome in PBMCs - A novel multiple-hit model for disease progression”.